We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences Grows on New Deals, Down on Coronavirus Scare
Read MoreHide Full Article
On Mar 23, we issued an updated research report on Exact Sciences Corporation (EXAS - Free Report) . Exact Science continues to make significant progress with its Cologuard test. The Genomic Health merger also buoys optimism. However, the coronavirus outbreak is causing share-price depreciation. Exact Sciences currently carries a Zacks Rank #3 (Hold).
Exact Sciences has demonstrated strength across its business, aided by impressive performances of the company’s Cologuard business. We look forward to Exact Science’s recently-closed merger with advanced molecular diagnostics company Genomic Health.
The Exact Sciences team is currently focusing on the three strategic priorities which are running its partnership with Pfizer; enhancing Cologuard; and advancing pipeline of blood-based cancer diagnostic tests. In terms of the first priority, the company is confident about capturing at least 40% of the U.S. colorectal cancer screening market from about 5% now.
In terms of the second priority to enhance Cologuard, last October, the FDA approved a label expansion providing access to Cologuard for the 19-million average risk unscreened Americans aged 45-49, and increasing its total addressable market by $3 billion to $18 billion. With regard to the third priority of advancing blood-based cancer diagnostic program, the combination with Genomic Health will build on its success of creating an even stronger growth platform for Cologuard, Oncotype DX and its pipeline.
Meanwhile, escalating expenses are straining the company’s operating margin. Sole reliance on Cologuard and competitive headwinds is a major downside. Further, the coronavirus-led market mayhem is resulting in share-price depreciation. The global supply chain disruption is significantly hurting the company's revenues as well, which will likely be reflected in the first-quarter results.
Over the past three months, Exact Sciences has been underperforming its industry. The stock plummeted 46.6% as compared with the industry's 19.9% decline.
Key Picks
Some better-ranked stocks in the broader medical space are ResMed Inc. (RMD - Free Report) , Medtronic plc (MDT - Free Report) and Hill-Rom Holdings, Inc. .
Medtronic’s long-term earnings growth rate is estimated at 7.1%. The company presently holds a Zacks Rank #2.
Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It currently carries a Zacks Rank of 2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Exact Sciences Grows on New Deals, Down on Coronavirus Scare
On Mar 23, we issued an updated research report on Exact Sciences Corporation (EXAS - Free Report) . Exact Science continues to make significant progress with its Cologuard test. The Genomic Health merger also buoys optimism. However, the coronavirus outbreak is causing share-price depreciation. Exact Sciences currently carries a Zacks Rank #3 (Hold).
Exact Sciences has demonstrated strength across its business, aided by impressive performances of the company’s Cologuard business. We look forward to Exact Science’s recently-closed merger with advanced molecular diagnostics company Genomic Health.
The Exact Sciences team is currently focusing on the three strategic priorities which are running its partnership with Pfizer; enhancing Cologuard; and advancing pipeline of blood-based cancer diagnostic tests. In terms of the first priority, the company is confident about capturing at least 40% of the U.S. colorectal cancer screening market from about 5% now.
Exact Sciences Corporation Price
Exact Sciences Corporation price | Exact Sciences Corporation Quote
In terms of the second priority to enhance Cologuard, last October, the FDA approved a label expansion providing access to Cologuard for the 19-million average risk unscreened Americans aged 45-49, and increasing its total addressable market by $3 billion to $18 billion. With regard to the third priority of advancing blood-based cancer diagnostic program, the combination with Genomic Health will build on its success of creating an even stronger growth platform for Cologuard, Oncotype DX and its pipeline.
Meanwhile, escalating expenses are straining the company’s operating margin. Sole reliance on Cologuard and competitive headwinds is a major downside. Further, the coronavirus-led market mayhem is resulting in share-price depreciation. The global supply chain disruption is significantly hurting the company's revenues as well, which will likely be reflected in the first-quarter results.
Over the past three months, Exact Sciences has been underperforming its industry. The stock plummeted 46.6% as compared with the industry's 19.9% decline.
Key Picks
Some better-ranked stocks in the broader medical space are ResMed Inc. (RMD - Free Report) , Medtronic plc (MDT - Free Report) and Hill-Rom Holdings, Inc. .
ResMed has a projected long-term earnings growth rate of 14.4%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic’s long-term earnings growth rate is estimated at 7.1%. The company presently holds a Zacks Rank #2.
Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It currently carries a Zacks Rank of 2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>